Form 4: John Morikis Receives JNJ Deferred Share Units

Director John G. Morikis acquired 1,540 deferred share units as part of the Johnson & Johnson director compensation plan.

Summary

• Director John G. Morikis was granted 1,540 deferred share units (DSUs) on April 23, 2026.
• The DSUs were issued under the Johnson & Johnson Amended and Restated Deferred Fee Plan for Directors.
• Each DSU represents the fair market value of one share of common stock and will be settled in cash upon the termination of the director's service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-linked compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The DSUs will be settled in cash upon the termination of the reporting person's directorship.

Industry Context

StockSavvy.ai notes that this is a standard regulatory disclosure for director compensation, reflecting routine corporate governance practices within the pharmaceutical and medical device sector.

Comparison to Industry Standards

• The use of deferred share units for board compensation is a standard practice among S&P 500 companies to ensure director alignment with long-term performance.
• The structure of the grant is consistent with typical governance policies for large-cap healthcare firms.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation disclosure.

Next Steps

• Settlement of units upon termination of directorship.

Key Dates

Keywords

Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4